Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A (FANCOLEN-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03157804|
Recruitment Status : Recruiting
First Posted : May 17, 2017
Last Update Posted : May 17, 2017
This is an open, Phase I / II clinical trial to evaluate the safety and efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi Anemia of Subtype A .
CD34 + cells derived from bone marrow and / or mobilized peripheral blood (fresh and / or cryopreserved) from patients with Fanconi subtype A (FA-A), will be transduced ex vivo with a lentiviral vector carrying the gene FANCA (orphan drug) . After transduction the cells will be inoculated in patients in order to restore their hematopoiesis with genetically corrected stem cells.
|Condition or disease||Intervention/treatment||Phase|
|Fanconi Anemia||Procedure: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs) Biological: Genetically Engineered Hematopoietic Stem/Progenitor Cells Other: Laboratory Biomarker Analysis Biological: Filgrastim Drug: Plerixafor Procedure: Bone Marrow Aspiration||Phase 1 Phase 2|
The main objective of this open-label Phase I / II clinical trial is to evaluate the safety and therapeutic efficacy of a hematopoietic gene therapy procedure with an orphan drug consisting of a lentiviral vector carrying the FANCA gene for patients with Fanconi's Anemia Subtype A.
The drug to be administered to the patients consists of the cellular product resulting from the transduction of autologous CD34 + cells with the therapeutic lentiviral vector PGK-FANCA.Wpre *.
The dose of cells to infuse in the patients will be that obtained from the transduction process of between 3x10^5 and 4x10^6 CD34 + cells / kg of patient body weight.
The cells will be infused intravenously in a single dose, after complete the transduction process.
Follow-up period: 2 years after infusion of transduced cells. However, patients will be monitored outside the clinical trial over a 10-year period.
Follow-up of the grafted transduced cells will be performed on peripheral blood and bone marrow samples.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Trial Phase I / II to Evaluate the Safety and Efficacy of the Infusion of Autologous CD34 + Cells Transduced With a Lentiviral Vector Carrying the Gene FANCA in Patients With FA Subtype A (FANCOLEN-1)|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||February 2019|
Experimental: Autologous CD34+ cells transducted with PGK-FANCA-Wpre *
CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
Procedure: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)
Biological: Genetically Engineered Hematopoietic Stem/Progenitor Cells
Undergo infusion of genetically modified hematopoietic progenitor cell therapy
Other Name: Genetically Engineered HSPCsOther: Laboratory Biomarker Analysis
Correlative studiesBiological: Filgrastim
Given subcutaneously (SC)
Other Name: Filgrastim XM02, Filgrastim-sndz, G-CSF (Colony Stimulating Factor), Neupogen, r-metHug-CSF, Recombinant Methionyl Human Granulocyte CSF, rG-CSF, Tbo-filgrastim, ZarxioDrug: Plerixafor
Other Name: AMD 3100, JM-3100, Mozobil, SDZ SID 791Procedure: Bone Marrow Aspiration
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Up to 2 years after infusion of transduced cells ]All adverse events will be registered for 2 years from infusion of transduced cells
- Proportion of patients with at least 0.1 copy of the therapeutic vector per nucleated bone marrow or peripheral blood cells two years after infusion. [ Time Frame: 2 years after infusion of transduced cells ]Detection of at least 0.1 copy of the therapeutic vector per nucleated bone marrow cell or peripheral blood cells two years after infusion.
- Proportion of patients with clinical hematological response after the infusion of autologous CD34 + cells transduced with the therapeutic lentiviral vector [ Time Frame: 2 years after infusion of transduced cells ]Proportion of patients with clinical hematological response (improvement of cell blood counts at least in one hematological lineage).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03157804
|Contact: Julian Sevilla||+34 firstname.lastname@example.org|
|Hospital Vall d'Hebron||Recruiting|
|Barcelona, Spain, 08035|
|Contact: Cristina Diaz de Heredia|
|Hospital Infantil del Niño Jesus||Recruiting|
|Madrid, Spain, 28009|
|Contact: Julian Sevilla 915035938 email@example.com|
|Study Director:||Juan A Bueren||CIEMAT/CIBERER/IIS.FJD|